Genomics Assets to Ocimum Biosolutions for $10 Million
Good to have that done. Next step in my mind is to allow
a reverse merger with some young emerging outfit.
COMPETITION
Drug Repositioning Division
Currently, an increasing number of pharmaceutical and biotechnology companies are evaluating whether to implement internal repositioning programs for their own drug candidates. In addition, there are companies attempting to reposition drug candidates on behalf of drug development partners, including Melior, KineMed, Perlegen Sciences, Inc., Vanda Pharmaceuticals Inc. and CombinatoRX Inc. We are not aware of any existing competitor that has developed, or is in the process of developing, a comparable suite of technologies to that employed by us. Other companies, some of whom are not doing repositioning work, have individual technologies that could directly compete with components of our drug repositioning technology platform.
Merge, retire old management, then rebirth.
Stocks are cyclical, change the symbol, start over. |
